Early use of renal-sparing agents in liver transplantation: A closer look

Liver Transplantation

Volumn 19, Issue 8, 2013, Pages 826-842

  Trotter, James F ^a   Grafals, Monica ^b   Alsina, Angel E ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c TAMPA GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS;

DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84881106970     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23672     Document Type: Review

References (46)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
2. Prakash J, Mahapatra AK, Ghosh B, Arora P, Jain AK,. Clinical spectrum of renal disorders in patients with cirrhosis of liver. Ren Fail 2011; 33: 40-46.
3. Ginès P, Schrier RW,. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290.
4. Schrier RW, Shchekochikhin D, Ginès P,. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transplant 2012; 27: 2625-2628.
5. Davis CL, Gonwa TA, Wilkinson AH,. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8: 91-109.
6. Kalambokis G, Christou L, Stefanou D, Arkoumani E, Tsianos EV,. Association of liver cirrhosis related IgA nephropathy with portal hypertension. World J Gastroenterol 2007; 13: 5783-5786.
7. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ,. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007; 7: 168-176.
8. Brown RS Jr, Lombardero M, Lake JR,. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 1788-1793.
9. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP,. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998; 54: 518-524.
10. Nair S, Verma S, Thuluvath PJ,. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 1179-1185.
11. Markmann JF, Markmann JW, Markmann DA, Bacquerizo A, Singer J, Holt CD, et al. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001; 72: 1113-1122.
12. O'Riordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ,. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21: 2630-2636.
13. Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, et al.; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1-S34.
14. Bahirwani R, Reddy KR,. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009; 15 (suppl 2): S70-S74.
15. Lee JP, Heo NJ, Joo KW, Yi NJ, Suh KS, Moon KC, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25: 2772-2785.
16. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ,. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009; 22: 49-60.
17. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12: 1855-1865.
18. Barri YM, Sanchez EQ, Jennings LW, Melton LB, Hays S, Levy MF, Klintmalm GB,. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009; 15: 475-483.
19. Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252-2262.
20. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12: 1640-1648.
21. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al.; for H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020.
22. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11: 965-976.
23. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al.; for ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327-336.
24. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-1072.
25. Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010; 89: 1504-1510.
26. Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009; 15: 1542-1552.
27. Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, et al. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl 2009; 15: 136-147.
28. Sanchez EQ, Melton LB, Chinnakotla S, Randall HB, McKenna GJ, Ruiz R, et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. Transplantation 2010; 89: 232-235.
29. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755-1760.
30. Schmeding M, Kiessling A, Neuhaus R, Heidenhain C, Bahra M, Neuhaus P, Neumann UP,. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation 2011; 92: 923-929.
31. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591.
32. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Liguori Carino N, De Luca L, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007; 13: 46-54.
33. Créput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B, et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 2007; 13: 1004-1010.
34. ClinicalTrials.gov. Liver Spare the Nephron (STN) Study-a study of CellCept (mycophenolate mofetil) and sirolimus in recipients of a liver transplant. http://www.clinicaltrials.gov/ct2/show/NCT00118742. Accessed April 2013.
35. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al.; for Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694-705.
36. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269.
37. Roche Trials Database. Clinical trial result information. http://www.roche-trials.com/studyResultGet.action?studyResultNumber=ML18423. Accessed April 2013.
38. McKenna GJ, Trotter JF,. Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details. Am J Transplant 2012; 12: 521-522.
39. Rapamune (Sirolimus) Oral Solution and Tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; 2011.
40. Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010; 52: 1360-1370.
41. Wiesner RH,. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499.
42. Tchao N, Sayre P, Feng S, Fung J, Klintmalm G, Punch J, et al. Long-term immunosuppression management in OLT recipients [abstract]. Am J Transplant 2007; 7 (suppl 2): 550.
43. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413-423.
44. Smith HE, Jones JP III, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008; 18: 943-953.
45. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661-674.
46. Capron A, Lerut J, Verbaandert C, Mathys J, Ciccarelli O, Vanbinst R, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit 2007; 29: 340-348.